case_images: PMC4037314_01
case_images: Juxtafoveolar subretinal choroidal neovascularization with subretinal fluid adjacent to the choroidal rupture 2 months after vitrectomy demonstrated by optical coherence tomography and fluorescein angiography.
case_images: opth-8-945Fig1.jpg
case_images: PMC4037314_01_opth-8-945Fig1.jpg
case_images: f1-opth-8-945
case_images: Optical coherence tomography and fluorescence angiography demonstrated a juxtafoveal type 2 CNV originating from the edge of the choroidal rupture (Figure 1).
case_images: Recurrence of the choroidal neovascularization activity with a central macular thickness of 349 mum.
case_images: opth-8-945Fig2.jpg
case_images: PMC4037314_01_opth-8-945Fig2.jpg
case_images: f2-opth-8-945
case_images: Three months later, the patient returned with a recurrence of CNV activity and increased central macular thickness (Figure 2).
case_images: Spectral-domain optical coherence tomography confirmed reduction of the choroidal neovascularization activity with a central macular thickness of 275 mum and disappearance of the retinal hemorrhage. Leakage from the choroidal neovascularization in the fluorescein angiography had ceased.
case_images: opth-8-945Fig3.jpg
case_images: PMC4037314_01_opth-8-945Fig3.jpg
case_images: f3-opth-8-945
case_images: Two additional bevacizumab injections were administered, achieving a final reduction in subretinal fluid and central macular thickness (Figure 3).